Overall survival results from the NETTER-1 trial in neuroendocrine tumours: an important milestone
Mené en Europe et aux Etats-Unis sur 231 patients atteints d'une tumeur neuroendocrine de l'intestin moyen, cet essai de phase III compare l'efficacité, du point de vue de la survie globale, et la toxicité d'un traitement combinant le lutétium-177-dotatate et l'octréotide à action prolongée et un traitement par hautes doses d'octréotide à action prolongée
Jonathan Strosberg and colleagues report the final overall survival and long-term safety results of the phase 3 NETTER-1study in patients with midgut neuroendocrine tumours (NETs). These data are the firstlong-term prospective results with the radiopharmaceutical 177Lu-Dotatate in patients with locally advanced or progressive, well differentiated,somatostatin receptor-positive midgut NETs with a Ki67 index of 20% or less. The primaryobjective of the NETTER-1 trial was met in 2017, showing a significantly longer progression-freesurvival in patients with these tumours following treatment with 177Lu-Dotatate in combination with long-acting octreotide (20–30 mg) versus high-dose(60 mg) long-acting octreotide alone (p=0·0001). However, the long-term results reported by Strosberg and colleagues do not show a significant improvement in overall survival with 177Lu-Dotatate.
The Lancet Oncology , 2021